Galantamine (GAL), an alkaloid used clinically for the symptomatic treatment of Alzheimer’s disease (AD), acts through reversible inhibition of AChE and modulation of nicotinic receptors, thereby facilitating cholinergic neurotransmission [23]. This evidence concerns the gene GAL and early-onset autosomal dominant Alzheimer disease.